Bioimpacts. 2018;8(3): 211-221. doi: 10.15171/bi.2018.24
PMID: 30211081        PMCID: PMC6128972

Original Research

A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model

Cited by CrossRef: 2

1- Martin Lluesma S, Graciotti M, Chiang C, Kandalaft L. Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. Vaccines. 2018;6(4):79 [Crossref]
2- Mookerjee A, Graciotti M, Kandalaft L. IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine. Cancers. 2019;11(1):40 [Crossref]

BioImpacts, as a peer-reviewed international journal, publishes all types of papers on bench-to-bedside translational aspects of pharmaceutical and biomedical sciences. As a "Publish Free" and "Access Free" journal, BioImpacts follows a constructive peer-review process with free editing service to benefit the scientific community worldwide.